Nilotinib is the same as Tasigna and is a drug that treats cancer...already FDA approved. They will have to make it a dual purpose drug that treats two diseases...cancer and Parkinson's. We shall see....soon I hope. Sterling

Further, by administering a low dose of anisomycin, which blocks protein production, the Dawson strategy also rescued flies with LRRK2 mutations.
Though these findings are exciting, we should remember that they have yet to be translated into humans. The Dawsons have suggested that one way to treat LRRK2 Parkinson’s disease would be to simply block phosphorylation of the s15 ribosomal protein. This idea may be formulated into a strategy for a future human clinical drug trial. Further, if there is a clinical trial, we will need a way to measure success and to monitor s15 phosphorylation. Phosphorylation could possibly be a blood or other biomarker of bad LRRK2 activity. The Dawsons have also for many years been investigating a class of drugs called the C-Abl tyrosine kinase inhibitors because of findings in another genetic form of Parkinson’s disease called PARKIN. The PARKIN protein is modified by c-Abl and this interaction could be the critical step leading to accumulation of toxic proteins in the brain. C-Abl inhibitors have been proposed as a way to block this protein buildup. The C-Abl pathway is where Nilotinib is thought to act, and this was proposed several years ago as a potential treatment for the protein buildups in Parkinson’s disease.
The Hopkins team carefully examined Nilotinib in 2013 (seehttp://www.ncbi.nlm.nih.gov/pubmed/24786396). “Our findings… suggest that Nilotinib and other brain penetrant c-Abl inhibitors could be used as disease modifying therapies in Parkinson’s disease. Consistent with this notion is the observation that Nilotinib reverses the loss of dopamine neurons and improves motor behavior in α-synuclein PD models. Based on the findings reported here and elsewhere, future studies are needed to identify the optimal dosing and administration to take advantage of the full neuroprotective potential of Nilotinib. Alternatively other c-Abl inhibitors with better pharmacokinetic properties and safety profiles may need to be identified to take advantage of inhibition of c-Abl as a disease modifying therapy for PD.”

The Michael J. Fox Foundation for Parkinson’s Research (MJFF), Van Andel Research Institute (VARI) and The Cure Parkinson’s Trust (CPT) announced on July 11, 2016 plans to collaborate on the clinical development of nilotinib, a chronic myelogenous leukemia drug that has shown potential in preliminary studies as a treatment for Parkinson’s disease. As part of these efforts, the organizations aim to design and co-fund a therapeutic development program including a double-blind, placebo-controlled clinical trial of nilotinib expected to begin in 2017.

Patients and clinicians are urged to wait for further safety data before considering adding the drug to their treatment regimens at this time. There is not yet enough information to assert that it works in Parkinson’s and, perhaps most critically, that it is safe to take long-term.

Here's a link to the press release :
https://www.cureparkinsons.org.uk/news/cpt-coll...

@A MyParkinsonsTeam Member,

Hi Sterling, I would like to thank you for your posts. I did clicked and tried to understand the researcher report, but it was hard for me to understsnd, but I more or less understood your post about this cancer drug that I hesrd about it here in MPT ( My Parkinson Team ), and at Michael Parkinson Foundation We do appreciate your educational post as well as your other posts. May you remain as always a beacon of light in this foggy journey called Parkinson Disease (PD). God Bless.

Mentioned Users

A MyParki...

Sterling , This is strictly my opinion; " DO NOT THAT THE FOLLOWING INFORMATION AND MEDICAL FACT, CONCEDERED MEDIAL FACT OR MEDICALLY APPROVED AND TEST APPROVED FDA CERTIFIED APPROVED INFORMATION."

In my experience, anything that first comes out in the us and is experional needs to always taken with a grain of salt for side effect can be very DANGERIOUS
Please check ou info from germany, Isreal, and Cornell